EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of BCS II/IV Drugs

Karine Rodriguez-Fernandez iD, José David Gómez-Mantilla, Suneet Shukla, Peter Stopfer, Peter Sieger, Victor Mangas-Sanjuán iD, Sheila Annie Peters

Clinical Pharmacokinetics · 2025

DOI: 10.1007/s40262-025-01473-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2025. Verfasst von Karine Rodriguez-Fernandez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Food-Drug Interactions, Models, Biological, Intestinal Absorption. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION AND OBJECTIVE: Physiologically based pharmacokinetic (PBPK) models are increasingly used to predict food effect (FE) but model parameterization is challenged by in vitro-in vivo (IVIV) disconnect and/or parameter nonidentifiability. To overcome these issues, we propose a simplified PBPK model, in which all solubility-driven processes are lumped into a single parameter, solubility, which is optimized against observed concentration-time data. METHODS: A set of commercially available biopharmaceutical classification system (BCS) II/IV compounds was selected to measure the solubility in a fasted state simulated intestinal fluid (FaSSIF) medium. The compounds were ranked from the lowest to the highest dose-adjusted FaSSIF solubility (FaSSIF/D) value and subdivided into three areas based on an upper and a lower limit: drugs with FaSSIF/D > upper limit having no FE, drugs with FaSSIF/D < lower limit having FE, and drugs between the limits said to be in the sensitivity range (SR), for which we tested the hypothesis that solubility-limited absorption (SLA) identified by simplified PBPK model can reliably predict positive FE if their exposures are not impacted by gut efflux or gut metabolism. RESULTS: We demonstrate, using a subset of drugs within SR for which PBPK models were available, that drugs with SLA exhibited a positive FE, while those with no SLA did not show FE. CONCLUSIONS: This proposal allows for a reliable binary prediction of FE to enable timely decisions on the need for pilot FE studies as well as the timing of pivotal FE studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Food-Drug InteractionsModels, BiologicalIntestinal AbsorptionSolubilityHumansPharmaceutical PreparationsFastingPharmacokineticsBiopharmaceutics

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Valencia, Spain.
  • Interuniversity Research Institute for Molecular Recognition and Technological Development, Polytechnic University of Valencia-University of Valencia, Valencia, Spain.
  • Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Straße 173, 55216, Ingelheim am Rhein, Germany.
  • Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397, Biberach a.d. Riss, Germany.
  • Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Straße 173, 55216, Ingelheim am Rhein, Germany. sheila.peters@boehringer-ingelheim.com.

ORCID-Profile: Karine Rodriguez-Fernandez, Victor Mangas-Sanjuán

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Rodriguez-Fernandez, K., Gómez-Mantilla, J. D., Shukla, S., Stopfer, P., Sieger, P., Mangas-Sanjuán, V., & Peters, S. A. (2025). Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of BCS II/IV Drugs. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01473-9

Vancouver

Rodriguez-Fernandez K, Gómez-Mantilla JD, Shukla S, Stopfer P, Sieger P, Mangas-Sanjuán V, et al. Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of BCS II/IV Drugs. Clinical Pharmacokinetics. 2025. doi:10.1007/s40262-025-01473-9

BibTeX
@article{RodriguezFernandez2025,
  author = {Rodriguez-Fernandez, Karine and Gómez-Mantilla, José David and Shukla, Suneet and Stopfer, Peter and Sieger, Peter and Mangas-Sanjuán, Victor and Peters, Sheila Annie},
  title = {Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of BCS II/IV Drugs},
  journal = {Clinical Pharmacokinetics},
  year = {2025},
  doi = {10.1007/s40262-025-01473-9}
}
Kostenlos starten →